Evidence map›Paper›PMID 25840710›Full record

ReviewAllergy, asthma & immunology research2015

Mold allergens in respiratory allergy: from structure to therapy.

Teresa E Twaroch, Mirela Curin, Rudolf Valenta, Ines Swoboda

Open access · hybridAbstract readReview
In one paragraph

Review in Allergy, asthma & immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 1 pooled it
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 1 synthesis or guideline pooled it, 216 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Plant MicrofungiInternational journal of molecular sciences · 2026
    Article
  5. Article
  6. Validity of anJournal of asthma and allergy · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. MicrofungusCells · 2025
    Article
  13. Article
  14. Characterisation ofJournal of fungi (Basel, Switzerland) · 2025
    Article
  15. In vitro Study of Fungus-Like OrganismsJournal of inflammation research · 2025
    Article
  16. Article
  17. The Potential Proallergenic Activity ofJournal of inflammation research · 2025
    Article
  18. Review
  19. Impact of Enolase in Allergic Disease.Current allergy and asthma reports · 2024
    Review
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Teresa E TwarochDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Mirela CurinDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Rudolf ValentaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. rudolf.valenta@meduniwien.ac.at.
Ines SwobodaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.; The Molecular Biotechnology Section, University of Applied Sciences, Campus Vienna Biocenter, Vienna, Austria.
Medical University of Vienna · ATVienna Biocenter · AT

Funding

Austrian Science Fund FWF F 4605
6 · The paper itself

Abstract

Allergic reactions to fungi were described 300 years ago, but the importance of allergy to fungi has been underestimated for a long time. Allergens from fungi mainly cause respiratory and skin symptoms in sensitized patients. In this review, we will focus on fungi and fungal allergens involved in respiratory forms of allergy, such as allergic rhinitis and asthma. Fungi can act as indoor and outdoor respiratory allergen sources, and depending on climate conditions, the rates of sensitization in individuals attending allergy clinics range from 5% to 20%. Due to the poor quality of natural fungal allergen extracts, diagnosis of fungal allergy is hampered, and allergen-specific immunotherapy is rarely given. Several factors are responsible for the poor quality of natural fungal extracts, among which the influence of culture conditions on allergen contents. However, molecular cloning techniques have allowed us to isolate DNAs coding for fungal allergens and to produce a continuously growing panel of recombinant allergens for the diagnosis of fungal allergy. Moreover, technologies are now available for the preparation of recombinant and synthetic fungal allergen derivatives which can be used to develop safe vaccines for the treatment of fungal allergy.

Indexed as

allergen structureFungal allergyrecombinant allergensspecific immunotherapy

Identifiers

PMID25840710
PMCPMC4397360
OpenAlexW2013292266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.